QB3

Are you a potential startup founder looking to connect with either a technical or business partner? Join us on Tuesday, May 20 from 5 - 7 pm Pacific (on Zoom) for the next Biotech Startup Speed Teaming event! This unique opportunity brings together technical experts with commercializable technologies and individuals with business expertise. ✅ Our goal?  To foster meaningful connections that could lead to successful startup teams! 🔍 Why Participate? Finding the right co-founder can be challenging when building a startup in the life sciences. Investors seek balanced teams. Our Speed Teaming event is designed to facilitate connections through a series of fast-paced one-on-one meetings. 💡 How It Works: Participants will engage in up to nine 10-minute sessions, allowing for dynamic discussions and potential partnerships. While not every meeting will lead to a match, past events hosted by our colleagues at #UCBerkeley Life Sciences Entrepreneurship Center have successfully formed new companies! 🗓️ Apply Now! Applications are open until May 7. Don’t miss your chance to connect with future co-founders! https://lnkd.in/gcM7heuY Let’s turn your entrepreneurial dreams into reality! Thanks to Darren Cooke & Mike Cohen for pioneering this format and showing how it's done.

It's on!

You’re invited! Join us for a two-day symposium April 23-24 at #UCBerkeley exploring the potential of #AI to advance #climatetech. Learn from academic researchers leveraging AI to accelerate discovery and hear from startup founders and industry experts leading the translation of impactful climate solutions. RSVP to reserve your spot today! We are organizing this together with the Bakar Institute of Digital Materials for the Planet. Full agenda on their website https://lnkd.in/g74BSA-5

What do autoimmune diseases—from lupus to rheumatoid arthritis—have in common? They are notoriously difficult to diagnose and treat. Both diagnosis and treatment represent huge unmet medical needs. That’s why QB3 brought together dedicated researchers, startup founders, and investors for “Innovation in Autoimmune Therapies from Discovery to Translation,” a symposium at Bakar Bio Labs this past Monday, March 24. We aimed to generate new ideas and connections that could lead to better treatments—and hopefully cures—for patients afflicted by these complex diseases. Read the event recap by Ruhani Chhabra here: https://lnkd.in/gWpMuXJY Thank you to our sponsors Goodwin (gold level) Kenneth Rainin Foundation and Johnson & Johnson Innovative Medicine (bronze level); and Lupus Research Alliance (supporting). Thank you to Katarina Klett (she/her) for conceiving and organizing this symposium, and to all our speakers! David Schaffer Bakar Bio Labs Mark Anderson, UCSF Diabetes Center Averil Ma, #UCSF Gregory M. BARTON, #UCBerkeley Robert Saxton, UC Berkeley Joe DeRisi, UCSF & Chan Zuckerberg Biohub Network Kate Williams Johnson & Johnson Tyler Chavez Biogen Maggie Louie Aqtual, Inc. Melanie M. LYRIC BIO Ena Ladi Genentech George Kwong Caribou Biosciences Maya Bader Lupus Research Alliance Alliance   Siquan Sun Johnson & Johnson Innovative Medicine Josh Gertsman Aditum Bio Renuka Nayak, Arthritis National Research Foundation

How to get funders interested in backing your therapy for autoimmune disease? Think ahead, says Siquan Sun, senior scientific director at Johnson & Johnson Innovative Medicine. 10 years ahead, to be precise. That is when your drug would be available to patients -- assuming all goes perfectly. What will be the standard of care for your disease indication in a decade and how will your drug compare to that -- not to some generic on the market today? Great insight from the panelists in our session on funding in the space yesterday, at our symposium on therapies for autoimmune disease, held at Bakar Bio Labs. We appreciated Maggie W. from our event gold sponsor Goodwin moderating the panel, which comprised Siquan and Maya Bader of the Lupus Research Alliance ; Josh Gertsman of Aditum Bio; and Renuka Nayak from #UCSF and the Arthritis National Research Foundation. The panel thought that these areas were particularly exciting at the moment: 🧑🔬 B cell depletion therapies (including cell therapies, antibodies, and t-cell engagers). 💊 Better oral drugs (this will increase adoption by patients). 💉Still a need for better delivery (how can we ensure that drugs are being delivered to target cells/tissues). 👩💻The use of multiomics to continue to better understand autoimmune diseases. Full recap to come! There was a LOT to cover. Event details at https://lnkd.in/gxRVUcJu Katarina Klett (she/her)

Excited to be part of the QB3 mentoring program and grateful for the support from Kaspar Mossman and the QB3 team! 🙌 As much as I love endless media changes (who doesn’t? 😆), I’d rather spend that time actually doing science. That’s why Open Culture Science is tackling hands-free, reproducible cell culture with automation, cloud scheduling, and open-source tools. Looking forward to learning from the amazing QB3 network, meeting labs that need better automation, and making sure our tech doesn't wither away unused! 🚀 If you're interested in automating tissue culture (or just tired of babysitting incubators), let's chat! #QB3 #LifeScienceEntrepreneurship #OpenCultureScience

Are you a scientist, founder, or investor passionate about making an impact on #autoimmune diseases? Each year QB3 organizes a scientific symposium in an area of high unmet need. The goal is to highlight advancements in the selected disease area and identify opportunities to accelerate progress. We use the event’s findings to motivate our Collaborative Research initiative with an eye towards developing therapeutics that will improve patient lives. This year, we are bringing together industry and academic scientists; potential funders; and companies, from startups to big pharma, committed to the mission of tackling autoimmune diseases. We invite you to apply to attend! https://lnkd.in/gYD4Bwh6

David Deamer, who invented the use of nanopores in sequencing, is participating in our SBIR grant workshop this cycle, looking to launch a company of his own.

Are you a researcher, startup, or investor interested in advancing therapies to treat #autoimmune disease? Join us Monday, March 24 for a symposium at Bakar Bio Labs to learn about cutting-edge autoimmune disease research and network with other passionate individuals in the ecosystem. https://lnkd.in/gYD4Bwh6

Hackathon alert: March 8-9 at #UCSF Mission Bay, Bay Area developers are joining with bioscientists to develop new tools for big data in life science. Learn more and get involved at https://lnkd.in/gGcY5fZP Klim Verba, Gina Nguyen & Asta Tijunelis Dauksa, MEd, QB3 colleagues from UCSF and Santa Cruz, were at UCSC recently to recruit participants.